Gossamer Bio (NASDAQ: GOSS) announced an FDA regulatory update and the reacquisition of worldwide rights to seralutinib, its investigational therapy for pulmonary arterial hypertension (PAH). The company also provided a broader business update outlining its strategy for advancing the program. Sector: Biotechnology Key Highlights 🧬 Reacquired worldwide rights to seralutinib 🏥 Announced an FDA regulatory update for the program 🌍 Gains full global control over the development and commercialization of seralutinib 📈 Shared a business update on future development plans Why It Matters Regaining worldwide rights gives Gossamer Bio greater strategic flexibility over seralutinib's development and commercialization. The FDA update also provides investors with important insight into the therapy's regulatory pathway. https://www.thinksabio.com/reports/isr/GOSS